Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Stability Assessment of Fresh or Cryopreserved Whole Blood and Bone Marrow Samples from AML and B-ALL Patients to Monitor CD123 Receptor and Immune Cells Subsets

Jacqueline Courta, Marielle Balzano, Wilfried Passe-Coutrin, Margaux Lagier, Karine Grivel, Daniele Boulay Moine, Drifa Beroual, Anne-Laure Bauchet, Geoffroy Venton, Regis Costello, Maxime Moulard

Blood (2023) 142 (Supplement 1): 6032.

https://doi.org/10.1182/blood-2023-179207

Published: 2023

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

Dual Targeting of ALDH1 and ALDH3: A Promising Therapeutic Approach in Acute Myeloid Leukemia

Mileidys Perez-Alea, Sr., PhD, Julien Colle, Jr., MD, Muhube Yazir, Jr., MSc, Céline Baier, Jr., PhD, Yasmine Labiad, PhD, Isabelle Arnoux, Sr., Hematologist, Geoffroy Venton, Jr., PhD MD, Guillaume Guillaume, MSc, Ismail Ceylan, MSc, Regis T. Costello, Sr., MD PhD

Blood (2019) 134 (Supplement_1): 3364.

https://doi.org/10.1182/blood-2019-126484

Published: 2019

Journal Articles

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Clemence Marcault, MD, Geoffroy Venton, Lauris Gastaud, MD, Lionel Mannone, MD, Jerome Rey, MD, Evelyne D'Incan, MD, Colombe Saillard, MD, Aude Charbonnier, MD, Sophie Raynaud, MD PhD, Norbert Vey, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 2615.

https://doi.org/10.1182/blood.V130.Suppl_1.2615.2615

Published: 2017

Journal Articles

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Pedro H Prata, MD, Cecile Bally, Thomas Prebet, MD PhD, Christian Recher, MD PhD, Geoffroy Venton, Xavier Thomas, MD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Thomas Cluzeau, MDPhD, Judith Desoutter, Julie Gay, Claude Preudhomme, PharmD, PhD, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2017) 130 (Supplement 1): 1335.

https://doi.org/10.1182/blood.V130.Suppl_1.1335.1335

Published: 2017

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Blood (2015) 126 (23): 5108.

https://doi.org/10.1182/blood.V126.23.5108.5108

Published: 2015

Journal Articles

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Jean El-Cheikh, MD PhD, Raynier Devillier, Roberto Crocchiolo, MD PhD, Sabine Furst, MD, Boris Calmels, Catherine Faucher, Anne Marie Stoppa, MD, Angela Granata, Claire Oudin, Patrick Ladaique, Claude Lemarie, Geoffroy Venton, Reda Bouabdallah, MD, Christine Zandotti, Pierre Berger, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4496.

https://doi.org/10.1182/blood.V120.21.4496.4496

Published: 2012

Journal Articles

Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant

Jean El-Cheikh, MD PhD, Geoffroy Venton, Roberto Crocchiolo, MD PhD, Sabine Furst, MD, Catherine Faucher, Angela Granata, Claire Oudin, Reda Bouabdallah, MD, Norbert Vey, MD, Segolene Duran, Pierre Berger, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4505.

https://doi.org/10.1182/blood.V120.21.4505.4505

Published: 2012

Journal Articles

High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+ Lymphomas

Sabine Furst, MD, Reda Bouabdallah, MD, Diane Coso, MD, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Catherine Faucher, MD, Angela Granata, Claire Oudin, Geoffroy Venton, Anne Marie Stoppa, Claude Lemarie, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 4526.

https://doi.org/10.1182/blood.V120.21.4526.4526

Published: 2012

Journal Articles

Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients

Geoffroy Venton, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Sabine Furst, MD, Angela Granata, Claire Oudin, Catherine Faucher, Diane Coso, MD, Reda Bouabdallah, MD, Pierre Berger, Norbert Vey, Patrick Ladaique, Christian Chabannon, MD, PhD, Michele Merlin, Didier Blaise, MD

Blood (2012) 120 (21): 4186.

https://doi.org/10.1182/blood.V120.21.4186.4186

Published: 2012

Journal Articles

The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.

Roberto Crocchiolo, MD PhD, Sabine Fuerst, MD, Jean El-Cheikh, MD PhD, Angela Granata, Claire Oudin, Geoffroy Venton, Norbert Vey, Reda Bouabdallah, MD, Anne Marie Stoppa, Florence Broussais, MD, Aude Charbonnier, MD, PhD, Claude Lemarie, Diane Coso, MD, Thomas Prebet, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 3029.

https://doi.org/10.1182/blood.V120.21.3029.3029

Published: 2012

Journal Articles

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Sabine Furst, MD, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Catherine Faucher, MD, Claire Oudin, Angela Granata, Geoffroy Venton, Claude Lemarie, Diane Coso, MD, Reda Bouabdallah, MD, Anne Marie Stoppa, Norbert Vey, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 3031.

https://doi.org/10.1182/blood.V120.21.3031.3031

Published: 2012

NARROW

Stability Assessment of Fresh or Cryopreserved Whole Blood and Bone Marrow Samples from AML and B-ALL Patients to Monitor CD123 Receptor and Immune Cells Subsets

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Dual Targeting of ALDH1 and ALDH3: A Promising Therapeutic Approach in Acute Myeloid Leukemia

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant

High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+ Lymphomas

Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients

The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only